Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Bladder cancer updates from the second half of 2026

Prof Alison Birtle, Dr Ignacio Duran, Prof Axel Merseburger, Dr José Domínguez-Escrig and Prof Morgan Rouprêt
Bladder cancer updates from the second half of 2026 ( Prof Alison Birtle, Dr Ignacio Duran, Prof Axel Merseburger, Dr José Domínguez-Escrig and Prof Morgan Rouprêt )
18 Nov 2026

Teclistamab improves depth of response and PFS in high-risk smouldering multiple myeloma

Dr Omar Nadeem - Dana-Farber Cancer Institute, Boston, USA
Teclistamab improves depth of response and PFS in high-risk smouldering multiple myeloma ( Dr Omar Nadeem - Dana-Farber Cancer Institute, Boston, USA )
13 Nov 2026

ESMO 2026: Bladder and kidney cancer roundup

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ESMO 2026: Bladder and kidney cancer roundup ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
2 Nov 2026

ESMO 2026: Prostate cancer roundup

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ESMO 2026: Prostate cancer roundup ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
2 Nov 2026

Outpatient administration of xaluritamig for mCRPC: Feasibility and safety

Prof William Kelly – Thomas Jefferson University, Philadelphia, USA
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety ( Prof William Kelly – Thomas Jefferson University, Philadelphia, USA )
30 Oct 2026

Personalised neoantigen vaccine plus radiotherapy improves progression free survival in advanced solid tumours

Prof Feng-Ming Spring Kong - The University of Hong Kong, Hong Kong
Personalised neoantigen vaccine plus radiotherapy improves progression free survival in advanced solid tumours ( Prof Feng-Ming Spring Kong - The University of Hong Kong, Hong Kong )
29 Oct 2026

Tarlatamab improves long term survival in previously treated small cell lung cancer

Prof Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA
Tarlatamab improves long term survival in previously treated small cell lung cancer ( Prof Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )
26 Oct 2026

Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
26 Oct 2026

Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
26 Oct 2026

Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer

Dr Tamim Niazi - McGill University, Montreal, Canada
Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer ( Dr Tamim Niazi - McGill University, Montreal, Canada )
26 Oct 2026

ESMO 2026: Surgery in high-risk localised prostate cancer

Prof Bertrand Tombal, Prof Thomas Steuber, Prof Gert Attard and Dr Mary-Ellen Taplin
ESMO 2026: Surgery in high-risk localised prostate cancer ( Prof Bertrand Tombal, Prof Thomas Steuber, Prof Gert Attard and Dr Mary-Ellen Taplin )
26 Oct 2026

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA
Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC ( Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Oct 2026